Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares (CANF) Stock Price

CANFStock

$1.76−72.16%52W

Market Cap$5.34M

P/E—

PEG Ratio—

Div yield—

Beta-0.62

CANF Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-56.13%

Price vs S&P 500 (4W)-8.96%

VGM Score42.12

Book Value / Share (Quarterly)$2.14

P/TBV (Annual)1.99x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-41.59%

Cash Flow / Share (Quarterly)$-3.42

Price vs S&P 500 (YTD)-109.75%

Net Profit Margin (TTM)-2422.41%

EPS (TTM)$-10.30

10-Day Avg Trading Volume0.01M

EPS Excl Extra (TTM)$-10.30

Revenue Growth (5Y)-12.49%

EPS (Annual)$-5.97

ROI (Annual)-175.75%

Gross Margin (Annual)90.62%

Net Profit Margin (5Y Avg)-1083.32%

Cash / Share (Quarterly)$2.11

Revenue Growth QoQ (YoY)-39.91%

ROA (Last FY)-103.30%

Revenue Growth TTM (YoY)-38.69%

EBITD / Share (TTM)$-10.70

ROE (5Y Avg)-151.64%

Operating Margin (TTM)-2446.13%

Cash Flow / Share (Annual)$-3.42

P/B Ratio1.06x

P/B Ratio (Quarterly)4.51x

Net Income / Employee (Annual)$-1,965,600

EV / Revenue (TTM)0.70x

Net Interest Coverage (TTM)-165.77x

ROA (TTM)-170.64%

EPS Incl Extra (Annual)$-5.97

Current Ratio (Annual)3.46x

Quick Ratio (Quarterly)3.13x

3-Month Avg Trading Volume0.02M

52-Week Price Return-72.16%

Revenue / Employee (TTM)$121,400

Tangible BV / Share (Quarterly)$0.03

P/S Ratio (Annual)14.70x

Asset Turnover (Annual)0.04x

52-Week High$9000000.00

Operating Margin (5Y Avg)-1099.72%

EPS Excl Extra (Annual)$-5.97

CapEx CAGR (5Y)-40.13%

Tangible BV CAGR (5Y)-2.26%

26-Week Price Return-46.23%

Quick Ratio (Annual)3.15x

13-Week Price Return-23.44%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.46x

Enterprise Value$425,000

Revenue / Share Growth (5Y)59.81%

Asset Turnover (TTM)0.07x

Book Value / Share Growth (5Y)176.98%

Revenue / Employee (Annual)$81,000

Pretax Margin (Annual)-2426.67%

Cash / Share (Annual)$2.11

3-Month Return Std Dev140.43%

Net Income / Employee (TTM)$-2,940,800

ROE (Last FY)-175.75%

Net Interest Coverage (Annual)-30.79x

EPS Basic Excl Extra (Annual)$-5.97

Receivables Turnover (TTM)0.23x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-10.30

Receivables Turnover (Annual)71.40x

ROI (TTM)-300.82%

P/S Ratio (TTM)9.81x

Pretax Margin (5Y Avg)-1083.30%

Revenue / Share (Annual)$0.25

Tangible BV / Share (Annual)$0.02

Price vs S&P 500 (52W)-70.54%

Year-to-Date Return-100.00%

5-Day Price Return-1.10%

EPS Normalized (Annual)$-5.97

ROA (5Y Avg)-87.60%

Net Profit Margin (Annual)-2426.67%

Month-to-Date Return-9.89%

EBITD / Share (Annual)$-6.03

Operating Margin (Annual)-2456.79%

ROI (5Y Avg)-151.64%

EPS Basic Excl Extra (TTM)$-10.30

P/TBV (Quarterly)1.05x

P/B Ratio (Annual)4.51x

Pretax Margin (TTM)-2422.41%

Book Value / Share (Annual)$2.14

Price vs S&P 500 (13W)-26.13%

Beta-0.62x

Revenue / Share (TTM)$0.37

ROE (TTM)-300.82%

52-Week Low$299.00

vGradeB

gGradeF

mGradeC

vgmGradeC

CANF Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2025	Aug 28, 2025	-$2.40	$0.00	+100.00%(+$2.40)

CANF Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.00

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
CANFCan-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares	B	F	C	9.8x	-38.7%	—	—	$1.76
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) Ordinary Shares

Can-Fite Biopharma is a clinical-stage biopharmaceutical company developing oral small-molecule drugs targeting the A3 adenosine receptor for cancer, inflammatory diseases, and liver disorders. The company's platform exploits selective A3AR expression in diseased cells, potentially enabling safer therapeutic efficacy. Its pipeline includes multiple candidates in Phase II and Phase III clinical development, including Namodenoson, Piclidenoson, and CF602.